Osimertinib Plus Chemotherapy Improves PFS in EGFR+ Advanced NSCLC
The combination of osimertinib and platinum-based chemotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.
Susan Galbraith Dana Farber Cancer Institute World Health Organization Oncology Research Fengp H Platinum Based Chemotherapy
Source: onclive.com